Want to see AU:AYA full AI Analyst Report?
Top Page
Artrya Limited
(Sydney:AYA)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$2.50
â–¼(-49.90% Downside)
Action:Reiterated
Date:10/16/26
The score is held down primarily by very weak financial performance (minimal revenue, large and worsening losses, and significant ongoing cash burn) and bearish technical trend signals (price below key moving averages and negative MACD). The low-debt balance sheet provides some stability, but valuation is hard to support given negative earnings and no dividend yield data.
Positive Factors
Low Leverage
Very low debt reduces near-term solvency pressure and limits interest obligations, preserving more flexibility for product development and commercial investment. This balance-sheet cushion is a durable strength even though it does not offset the company’s current losses or cash consumption.
Negative Factors
Minimal Revenue and Deep Losses
The very small revenue base shows that commercialization has not yet translated into meaningful financial scale. Losses substantially exceeding revenue indicate that operating costs remain far above current business activity, making a durable path to profitability dependent on major growth.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Very low debt reduces near-term solvency pressure and limits interest obligations, preserving more flexibility for product development and commercial investment. This balance-sheet cushion is a durable strength even though it does not offset the company’s current losses or cash consumption.
Read all positive factors
Artrya Limited (AYA) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$453.27M
Dividend YieldN/A
Average Volume (3M)1.98M
Price to Earnings (P/E)―
Beta (1Y)2.96
Revenue Growth<0.01%
EPS Growth2.08%
CountryAU
Employees43
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)-0.17
Shares Outstanding163,633,620
10 Day Avg. Volume1,465,351
30 Day Avg. Volume1,977,280
Financial Highlights & Ratios
PEG Ratio6.46
Price to Book (P/B)11.56
Price to Sales (P/S)32321.70
P/FCF Ratio-56.88
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$5.18Price Target Upside3.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.14
Revenue Forecast (FY)AU$2.45M
Artrya Limited Business Overview & Revenue Model
Company Description
Artrya Limited is a medical technology firm that harnesses artificial intelligence (AI) to pinpoint individuals at risk of developing coronary artery disease. The company's key offering is Salix, a cloud-based software application. Salix leverages...
How the Company Makes Money
Artrya’s primary revenue model is expected to come from commercializing its AI-powered cardiovascular analysis software to healthcare providers, typically through software licensing and/or subscription (software-as-a-service) arrangements. Under t...
Artrya Limited Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
64
Positive
Cash Flow
14
Very Negative
| Breakdown | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.00K | 28.00K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -1.23M | -15.99M | -13.25M | -552.00K | -202.00K |
| EBITDA | -26.04M | -15.42M | -12.36M | -10.51M | -16.40M |
| Net Income | -25.18M | -16.41M | -14.00M | -11.14M | -17.16M |
Balance Sheet | |||||
| Total Assets | 85.35M | 23.68M | 19.01M | 33.09M | 43.87M |
| Cash, Cash Equivalents and Short-Term Investments | 74.17M | 11.33M | 7.28M | 20.41M | 35.56M |
| Total Debt | 247.00K | 624.00K | 949.00K | 1.21M | 1.37M |
| Total Liabilities | 7.06M | 2.39M | 2.21M | 2.53M | 3.23M |
| Stockholders Equity | 78.29M | 21.29M | 16.80M | 30.56M | 40.64M |
Cash Flow | |||||
| Free Cash Flow | -15.91M | -14.53M | -15.41M | -16.69M | -15.99M |
| Operating Cash Flow | -15.77M | -14.27M | -15.41M | -10.74M | -9.61M |
| Investing Cash Flow | -30.50M | 7.00K | 2.71M | 16.27M | -26.59M |
| Financing Cash Flow | 79.00M | 18.46M | -299.00K | -245.00K | 38.53M |
Artrya Limited Technical Analysis
Negative
4.99
Price Trends
3.53
Negative
4.33
Negative
4.09
Negative
Market Momentum
-0.28
Negative
41.16
Neutral
80.61
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:AYA, the sentiment is Negative. The current price of 4.99 is above the 20-day moving average (MA) of 2.87, above the 50-day MA of 3.53, and above the 200-day MA of 4.09, indicating a bearish trend. The MACD of -0.28 indicates Negative momentum. The RSI at 41.16 is Neutral, neither overbought nor oversold. The STOCH value of 80.61 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:AYA.
Artrya Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
65 Neutral | AU$35.31M | 23.13 | 13.72% | ― | 42.25% | ― | |
65 Neutral | AU$148.48M | 64.71 | 2.53% | ― | 26.61% | 41.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | AU$61.10M | -6.84 | -24.29% | ― | -17.35% | -47.29% | |
45 Neutral | AU$21.26M | -1.14 | -58.13% | ― | 2.08% | -195.31% | |
44 Neutral | AU$453.27M | -15.92 | -30.04% | ― | <0.01% | 2.08% | |
44 Neutral | AU$58.70M | -8.87 | -57.06% | ― | 603.32% | 10.57% |
* Healthcare Sector Average
AU:AYA
Artrya Limited
2.77
-0.64
-18.77%
AU:M7T
Mach7 Technologies
0.26
-0.04
-13.33%
AU:RHT
Resonance Health Ltd
0.07
0.02
51.02%
AU:BMT
Beamtree Holdings Ltd
0.07
-0.15
-67.27%
AU:SHG
Singular Health Group Ltd
0.18
-0.10
-36.84%
AU:ALC
Alcidion Group Limited
0.11
0.02
22.22%
Artrya Limited Corporate Events
UBS Group AG Exits Substantial Shareholding in Artrya Limited
Oct 26, 2026
UBS Group AG and its related bodies corporate have lodged a notice stating they have ceased to be a substantial holder in Artrya Limited as of 22 October 2026. The change in UBS’s relevant interest in Artrya voting securities marks a reducti...
Artrya lands largest U.S. customer as Salix rollout gains momentum
Oct 25, 2026
Artrya reported strong progress in its U.S. commercial rollout for the September quarter, highlighted by a five-year agreement with Huntsville Hospital Health System, its largest customer to date and the first conversion from its SAPPHIRE study pr...
Artrya Sets Date for September Quarter Report and Investor Webinar
Oct 21, 2026
Artrya Limited will release its September 2026 Quarterly Activities and Cashflow Report on Monday, 26 October 2026, providing investors with an update on the company’s operational and financial performance. The timing underscores the company...
Artrya Shifts to Digital Communications for 2026 AGM as It Formalises Meeting Arrangements
Oct 14, 2026
Artrya Limited has convened its 2026 Annual General Meeting for 13 November 2026 at its West Perth headquarters, setting a record date of 11 November 2026 for shareholder voting eligibility. The notice underscores that all voting will be conducted...
Artrya Seeks ASX Quotation for 200,000 New Shares
Oct 6, 2026
Artrya Limited has applied for quotation on the ASX of 200,000 new ordinary fully paid shares under the code AYA, effective 6 October 2026. The additional securities, issued following the exercise or conversion of existing instruments, will modest...
Artrya boosts capital base with issue of 200,000 incentive shares
Oct 6, 2026
Artrya Limited has issued 200,000 fully paid ordinary shares following the exercise of vested employee incentive performance rights, modestly increasing its share capital base. The new shares, which are the subject of an Appendix 2A quotation requ...
Artrya Secures Five-Year U.S. Salix Deal with Huntsville Hospital Health System
Oct 1, 2026
Artrya Limited has signed a five-year commercial agreement with Huntsville Hospital Health System, converting the U.S. cardiovascular centre from a SAPPHIRE Study participant into a commercial customer and expanding Artrya’s U.S. client base...
State Street Group Ceases to Be Substantial Holder in Artrya Limited
Sep 30, 2026
Artrya Limited has disclosed that State Street Global Advisors, Australia, Limited and related State Street Corporation subsidiaries have ceased to be substantial holders in the company as of 28 September 2026. The change in substantial holding st...
Wilson Asset Management exits substantial holding in Artrya
Sep 18, 2026
Artrya Limited has disclosed that Wilson Asset Management Group has ceased to be a substantial shareholder in the company, as recorded in a statutory Form 605 notice under Australia’s Corporations Act. The notice indicates that Wilson Asset ...
Artrya adds 13,334 new shares to ASX listing
Sep 16, 2026
Artrya Limited has applied to the ASX for quotation of an additional 13,334 ordinary fully paid shares under its existing ticker AYA. The new securities, issued on 16 September 2026, arise from the exercise or conversion of existing options or oth...
Artrya Issues New Shares Under Employee Incentive Plan
Sep 16, 2026
Artrya Limited has issued 13,334 fully paid ordinary shares following the exercise of vested employee incentive performance rights, a small increase to its share capital that reflects ongoing use of equity-based remuneration. The company will seek...
Artrya adds 6,667 new shares to ASX quotation
Sep 14, 2026
Artrya Limited has applied to the ASX for quotation of 6,667 new ordinary fully paid shares, issued on 14 September 2026 under the ticker AYA. The additional securities arise from the exercise or conversion of existing options or other convertible...
Artrya issues new shares on employee incentive rights exercise and confirms regulatory compliance
Sep 14, 2026
Artrya Limited has issued 6,667 fully paid ordinary shares following the exercise of vested employee incentive performance rights, a small equity issuance that marginally increases the company’s share base while reinforcing its use of equity...
Artrya Seeks ASX Quotation for Additional Ordinary Shares
Sep 8, 2026
Artrya Limited, listed on the ASX under the code AYA, offers ordinary fully paid shares as its core listed securities, providing investors with tradable equity in the company through the Australian Securities Exchange. Its corporate structure and ...
Artrya Issues New Shares Under Employee Incentive Plan and Confirms Compliance
Sep 8, 2026
Artrya Limited has issued 53,334 fully paid ordinary shares following the exercise of vested employee incentive performance rights, a move that slightly increases its share capital while reinforcing its staff remuneration framework. The company ha...
Artrya Added to S&P/ASX 300 in September Index Rebalance
Sep 4, 2026
SP Dow Jones Indices has announced its September 2026 quarterly rebalance of the SP/ASX indices, implementing a series of additions and removals across the SP/ASX 50, 100, 200, and 300. Among these changes, Artrya Limited is set to join the SP/ASX...
Artrya Seeks ASX Quotation for Additional Ordinary Shares
Sep 1, 2026
Artrya Limited has applied to the ASX for quotation of 10,000 ordinary fully paid shares, with the new securities to be issued on 1 September 2026. The modest share issuance reflects routine capital management activity and slightly expands the com...
Artrya issues new shares under employee incentive plan and confirms regulatory compliance
Sep 1, 2026
Artrya Limited has issued 10,000 ordinary shares following the exercise of vested employee incentive performance rights, reflecting the company’s ongoing use of equity-based remuneration to retain and motivate staff. The company has lodged a...
Artrya Issues New Shares on Employee Incentive Conversion
Aug 27, 2026
Artrya Limited has issued 130,002 ordinary shares following the exercise of vested employee incentive performance rights, expanding its share capital as part of its remuneration and incentive framework. The company also confirmed that the new shar...
Artrya Seeks ASX Quotation for Additional Ordinary Shares
Aug 25, 2026
Artrya Limited, listed on the ASX under the code AYA, has lodged an application for quotation of additional ordinary fully paid shares. The filing confirms the company’s identity and registration details but does not disclose specific inform...
Artrya issues new shares on employee incentives and lodges cleansing notice
Aug 25, 2026
Artrya Limited has issued 256,666 fully paid ordinary shares following the exercise of vested employee incentive performance rights and restricted stock units, and has applied for their quotation on the ASX. The move modestly increases the company...
Artrya strengthens board with appointment of healthcare veteran Helen Kurincic
Aug 19, 2026
Artrya Limited has appointed experienced healthcare and imaging executive Helen Kurincic as a Non-Executive Director, effective 20 August 2026, to strengthen its board as the company scales commercial operations. Kurincic brings more than three de...
Artrya lodges ASX corporate governance statement for FY 2026
Aug 19, 2026
Artrya Limited has lodged its annual corporate governance statement for the year ended 30 June 2026, confirming compliance with ASX Corporate Governance Council principles. The statement, approved by the board, is hosted on the company’s web...
Artrya Details 2026 Governance Framework and Committee Approach
Aug 19, 2026
Artrya Limited has released its 2026 Corporate Governance Statement, confirming broad adherence to the ASX Corporate Governance Council’s fourth edition principles. The board has adopted a formal charter defining roles for directors, the cha...
Artrya Widens Annual Loss but Boosts Net Tangible Assets
Aug 19, 2026
Artrya Limited reported revenue from ordinary activities of just $28,000 for the year ended 30 June 2026 and a significantly wider net loss after tax of $25.2 million, up 53.5% on the prior year. No dividends were paid or declared, and basic and d...
UBS Group AG Exits Substantial Shareholding in Artrya Limited
Aug 3, 2026
UBS Group AG and its related bodies corporate have notified Artrya Limited that they ceased to be a substantial shareholder in the company as of 30 July 2026. The change in UBS’s relevant interest in Artrya’s voting securities reflects...
Artrya accelerates U.S. rollout of AI cardiac platform as FDA-ready flow module nears launch
Jul 28, 2026
Artrya reported accelerating U.S. adoption of its Salix platform, with Tanner Health now using Salix Coronary Anatomy and Plaque routinely across five hospitals and Northeast Georgia Health System going live as a second revenue-generating customer...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.